Ascendis Pharma A/S (ASND) and Neurotrope Inc. (NASDAQ:NTRP) Comparing side by side

Ascendis Pharma A/S (NASDAQ:ASND) and Neurotrope Inc. (NASDAQ:NTRP) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ascendis Pharma A/S 110 -0.93 35.86M -3.74 0.00
Neurotrope Inc. 1 0.00 9.60M -1.47 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Ascendis Pharma A/S and Neurotrope Inc.

Profitability

Table 2 represents Ascendis Pharma A/S (NASDAQ:ASND) and Neurotrope Inc. (NASDAQ:NTRP)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S 32,582,227.88% -34.9% -31.9%
Neurotrope Inc. 1,319,224,955.34% -77.2% -70.4%

Volatility and Risk

Ascendis Pharma A/S’s current beta is 0.62 and it happens to be 38.00% less volatile than S&P 500. Competitively, Neurotrope Inc. is 130.00% more volatile than S&P 500, because of the 2.3 beta.

Liquidity

Ascendis Pharma A/S has a Current Ratio of 22.3 and a Quick Ratio of 22.3. Competitively, Neurotrope Inc.’s Current Ratio is 23.1 and has 23.1 Quick Ratio. Neurotrope Inc.’s better ability to pay short and long-term obligations than Ascendis Pharma A/S.

Analyst Recommendations

Ascendis Pharma A/S and Neurotrope Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ascendis Pharma A/S 0 0 4 3.00
Neurotrope Inc. 0 0 0 0.00

Ascendis Pharma A/S has a 32.59% upside potential and a consensus price target of $154.

Institutional and Insider Ownership

The shares of both Ascendis Pharma A/S and Neurotrope Inc. are owned by institutional investors at 0% and 16.2% respectively. Competitively, 18.97% are Neurotrope Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ascendis Pharma A/S 0.35% -2.64% 0.32% 60.62% 73.22% 84.77%
Neurotrope Inc. 0.09% -31.83% -19.24% 20.23% -46.89% 48.18%

For the past year Ascendis Pharma A/S’s stock price has bigger growth than Neurotrope Inc.

Summary

Ascendis Pharma A/S beats on 6 of the 11 factors Neurotrope Inc.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Neurotrope, Inc., a biopharmaceutical company, focuses on developing therapeutic and diagnostic technologies in the field of neurodegenerative diseases in the United States. The companyÂ’s lead product candidate is bryostatin-1, a natural product isolated from a marine invertebrate organism, which is in a Phase II trial for the treatment of moderate to severe AlzheimerÂ’s dementia, as well as in preclinical studies as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease, and Rett Syndrome. It has a license agreement with the Leland Stanford Junior University to sublicense Bryologs that are structural derivatives of Bryostatin for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate, NRV II, LLC. The company was founded in 2012 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.